Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter(Sheba Medical Center), Antoni Ribas(University of California, Los Angeles), Georgina V. Long(The University of Sydney), Ana Arance(Hospital Clínic de Barcelona), Jean‐Jacques Grob(Aix-Marseille Université), Laurent Mortier(Inserm), Adil Daud(University of California, San Francisco), Matteo S. Carlino(The University of Sydney), Catriona M. McNeil(Royal Prince Alfred Hospital), Michal Lotem(Hadassah Medical Center), James Larkin(Royal Marsden Hospital), Paul Lorigan(University of Manchester), Bart Neyns(Universitair Ziekenhuis Brussel), Christian U. Blank(The Netherlands Cancer Institute), Teresa M. Petrella(Sunnybrook Health Science Centre), Omid Hamid(Angeles Clinic and Research Institute), Honghong Zhou(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States)), Caroline Robert(Université Paris-Sud)
Cited by 1,230
Abstract
Related Papers
No related papers found
Powered by citation graph analysis